Good and bad news for Cambridge kits
This article was originally published in Clinica
Executive Summary
The US Bankruptcy Court has upheld Cambridge Biotech's licence under two patents issued to the Institut Pasteur for HIV-2 tests. However, it also ruled that Cambridge Biotech's HIV-1 Western blot confirmatory test infringes a third patent issued to the Institut Pasteur and so prevents the company from manufacturing and selling it. The latter test accounted for less than 15% of the company's diagnostic revenue in 1994, says Cambridge, which says it will appeal the decision.